AbbVie
ABBV
$136.44
Share price
-0.81%
Change (1 day)
-7.42%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Total assets
Total assets on the balance sheet as of December 2022 : $138.80 B
According to AbbVie's latest financial reports the company's total assets are $138.80 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
AbbVie - Total assets on balance sheet (from 2011 to 2022)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-12-31 | $138.80 B | -5.27% |
| 2021-12-31 | $146.52 B | -2.68% |
| 2020-12-31 | $150.56 B | 68.96% |
| 2019-12-31 | $89.11 B | 50.15% |
| 2018-12-31 | $59.35 B | -16.15% |
| 2017-12-31 | $70.78 B | 7.09% |
| 2016-12-31 | $66.09 B | 24.6% |
| 2015-12-31 | $53.05 B | 92.58% |
| 2014-12-31 | $27.54 B | -5.65% |
| 2013-12-31 | $29.19 B | 8.11% |
| 2012-12-31 | $27.00 B | 37.4% |
| 2011-12-31 | $19.65 B | -6.99% |
| 2010-12-31 | $21.13 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $197.20 B | 42.07% | 🇺🇸 USA |
 Eli Lilly LLY | $53.16 B | -61.70% | 🇺🇸 USA |
 Amgen AMGN | $88.72 B | -36.08% | 🇺🇸 USA |
 Biogen BIIB | $24.59 B | -82.28% | 🇺🇸 USA |
 Gilead Sciences GILD | $61.87 B | -55.42% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $94.28 B | -32.08% | 🇺🇸 USA |
 AstraZeneca AZN | $96.68 B | -30.34% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $72.58 B | -47.71% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $2.35 B | -98.30% | 🇺🇸 USA |